### ü§ñ AI in Drug Discovery - Nova $TAO Subnet 68

This article summarizes a podcast episode discussing the application of AI in drug discovery, specifically within the context of Nova $TAO Subnet 68 and its role in molecular search.  The episode also touches upon patenting and community value considerations.

Key Points:

‚Ä¢ AI accelerates drug discovery by streamlining molecular search.


‚Ä¢ AI aids in identifying promising drug candidates.


‚Ä¢  Patenting and community value are discussed in the context of AI-driven discoveries.


üîó Resources:

‚Ä¢ [MetaNova Labs](https://x.com/metanova_labs) - AI drug discovery company


‚Ä¢ [Hash Rate Podcast](https://x.com/markjeffrey/status/1899257895805694131) - Episode 99 featuring MetaNova Labs


‚Ä¢ [micaelabazo](https://x.com/micaelabazo) - MetaNova Labs guest


‚Ä¢ [pennapdr](https://x.com/pennapdr) - MetaNova Labs guest


![Image](https://pbs.twimg.com/amplify_video_thumb/1899250507069390848/img/gL677-oENPIrU8AQ.jpg)


---
### üí° Health2Tech Event - Digital Health Startup Extinction

This article announces a Health2Tech event featuring a presentation on the challenges facing digital health startups.

Key Points:

‚Ä¢  Presentation on the "Mass Extinction of Digital Health Startups."


‚Ä¢ Event takes place March 19th in New York.


‚Ä¢ Partnership with AIHealthUncut, jcness, and StartupGrindNYC.



üîó Resources:

‚Ä¢ [AIHealthUncut](https://x.com/AIHealthUncut) - Speaker at the event


‚Ä¢ [Health2Tech](https://lu.ma/d7pysz3i) - Event page


‚Ä¢ [jcness](https://x.com/jcness) - Partner organization


‚Ä¢ [StartupGrindNYC](https://x.com/StartupGrindNYC) - Partner organization



![Image](https://pbs.twimg.com/media/Glskv_ZWUAAtw77?format=jpg&name=small)


---
### ‚ú® Health Data Rewards - $RJV Token

This article describes a tokenized reward system for user engagement with health data.

Key Points:

‚Ä¢  Users earn rewards for contributing health data.


‚Ä¢  Connects with wearable devices.


‚Ä¢ Rewards users for their participation in their longevity journey.


üîó Resources:

‚Ä¢ [Rejuve AI](https://x.com/Rejuve_AI) -  Developer of the $RJV token


![Image](https://pbs.twimg.com/media/GltU2p0XAAAz2_y?format=jpg&name=small)


---
### ü§ñ Access to GLP-1 Medications - Cost Barriers

This article highlights a Scientific American article discussing cost barriers to accessing GLP-1 medications.

Key Points:

‚Ä¢ High cost of GLP-1 medications is a significant barrier for patients.


‚Ä¢ Patients often stop taking GLP-1s due to cost, impacting their health.


‚Ä¢  The article explores the reasons behind patients discontinuing treatment.



üîó Resources:

‚Ä¢ [Truveta](https://x.com/truveta) -  Source of the information


‚Ä¢ [Scientific American](https://x.com/sciam) - Publication featuring the article


![Image](https://pbs.twimg.com/media/GltTqFjXAAAXXvm?format=jpg&name=small)
![Image](https://pbs.twimg.com/media/GltTrVBX0AAdpYy?format=jpg&name=small)


---
### ü§ñ Top GU Cancer Trials - February 2025

This article presents a curated list of the top 10 clinical trials in genitourinary (GU) cancer for February 2025.

Key Points:

‚Ä¢ Top 10 GU cancer trials curated by Larvol CLIN and Bluestar BioAdvisors.


‚Ä¢  List includes trials like TALAPRO2, CheckMate274, and NIAGARA.


‚Ä¢  Provides insights into current oncology research.



üîó Resources:

‚Ä¢ [Larvol](https://x.com/Larvol) - Curator of the clinical trial list


![Image](https://pbs.twimg.com/media/GligkGhb0AASRlY?format=png&name=360x360)
![Image](https://pbs.twimg.com/media/Gligl2yaUAAtHQQ?format=png&name=360x360)
![Image](https://pbs.twimg.com/media/Gligng0bAAELiC_?format=png&name=360x360)
![Image](https://pbs.twimg.com/media/GligopOawAEnf25?format=png&name=360x360)


---
### üí° Cancer Risk Factors - Understanding Your Risk

This article discusses the importance of understanding cancer risk factors to make informed health decisions.

Key Points:

‚Ä¢ Cancer risk is influenced by genetics, lifestyle, and environment.


‚Ä¢ Understanding risk allows for proactive health management.


‚Ä¢  Risk factors include family history, lifestyle choices, and environmental exposures.


üîó Resources:

‚Ä¢ [MassiveBio](https://x.com/MassiveBio) - Source of the infographic


![Image](https://pbs.twimg.com/media/Glb5ybDX0AAY8Oy?format=jpg&name=small)
![Image](https://pbs.twimg.com/media/Glb5ya7XgAAk8EK?format=jpg&name=small)
![Image](https://pbs.twimg.com/media/Glb5ya7XcAAlSzd?format=jpg&name=small)
![Image](https://pbs.twimg.com/media/Glb5ya9XIAAhEZm?format=jpg&name=small)


---
### üí° Injury Recovery - The PEACE Principles

This article outlines the PEACE principles for injury recovery.

Key Points:

‚Ä¢ PEACE stands for Protection, Elevation, Avoid, Compression, Education.


‚Ä¢  Provides a framework for effective injury management.


‚Ä¢ Emphasizes self-care and informed decision-making in recovery.


üîó Resources:

‚Ä¢ [EQL AI](https://x.com/EQL_AI) - Source of the PEACE principles


---
### ü§ñ AI in Pathology - Owkin Dx Blog Series

This article announces a whitepaper on AI pathology models.  The whitepaper will discuss transitioning from traditional slide analysis to AI-powered medical devices.

Key Points:

‚Ä¢  Explores the transition from traditional microscopy to AI in pathology.


‚Ä¢ Highlights the crucial role of data in AI pathology model creation.


‚Ä¢  Provides a comprehensive analysis of AI pathology model development.


üîó Resources:

‚Ä¢ [Owkin Science](https://x.com/OwkinScience) - Publisher of the whitepaper


![Image](https://pbs.twimg.com/ext_tw_video_thumb/1897591151076507650/pu/img/7UyIcMZ_uPp0i8JB.jpg)


---
### ü§ñ AI and Health Equity - Qure.ai's TB Initiative

This article discusses how AI can contribute to health equity, using Qure.ai's tuberculosis (TB) initiative as an example.

Key Points:

‚Ä¢  AI technology assists in the fight against tuberculosis.


‚Ä¢  The initiative supports TB survivors globally.


‚Ä¢  The company emphasizes its commitment to improving health equity.


üîó Resources:

‚Ä¢ [Qure.ai](https://x.com/qure_ai) - Developer of the AI technology


![Image](https://pbs.twimg.com/ext_tw_video_thumb/1897565568271835140/pu/img/yRNMCuVTiFnnUCr9.jpg)


---
### ü§ñ AGI vs. LLM - Model Context Protocol (MCP)

This article discusses the differences between Artificial General Intelligence (AGI) and Large Language Models (LLMs), focusing on the Model Context Protocol (MCP).

Key Points:

‚Ä¢ AGI is self-evolving and self-emerging software.


‚Ä¢ LLMs, AI agents, and MCP are not considered AGI.


‚Ä¢  A sufficiently intelligent LLM might render MCP unnecessary.


üîó Resources:

‚Ä¢ [0xTsuan](https://x.com/0xTsuan) - Source of the discussion


![Image](https://pbs.twimg.com/media/GlV40HiaQAArL4c?format=jpg&name=small)


---

### ‚≠êÔ∏è Support

If you liked reading this report, please star ‚≠êÔ∏è this repository and follow me on [Github](https://github.com/Drix10), [ùïè (previously known as Twitter)](https://x.com/DRIX_10_) to help others discover these resources and regular updates.

---